<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Research - Sharma Lab</title>
  <link rel="stylesheet" href="styles.css" />
</head>
<body>
  <header>
    <h1>Ajay Kumar Sharma Lab</h1>
    <nav>
      <ul>
        <li><a href="index.html">Home</a></li>
        <li><a href="research.html" class="active">Research</a></li>
        <li><a href="team.html">Team</a></li>
        <li><a href="publications.html">Publications</a></li>
        <li><a href="news.html">News</a></li>
        <li><a href="gallery.html">Gallery</a></li>
        <li><a href="contact.html">Contact</a></li>
      </ul>
    </nav>
  </header>

  <main>
    <section>
      <h2>Our Research Focus</h2>
      <p>Our lab specializes in designing and synthesizing innovative peptides, antibody-drug conjugates, and peptide-drug conjugates for cancer imaging and therapy. We leverage expertise in multistep organic synthesis, chromatographic methods for purification, and characterization techniques such as NMR and mass spectrometry (LC-MS and MALDI-TOF). Our primary focus is developing novel methodologies for radiosynthesis to generate molecularly targeted small molecules and peptide-based radiopharmaceuticals utilizing radionuclides (<sup>18</sup>F, <sup>64</sup>Cu, <sup>68</sup>Ga, <sup>177</sup>Lu, <sup>225</sup>Ac) for cancer imaging and therapy.</p>

      <div class="research-areas">
        <h3>Key Research Areas</h3>
        
        <div class="research-area">
          <h4>üéØ Targeted Radiopharmaceutical Development</h4>
          <ul>
            <li><strong>EphA2-targeted theranostics</strong> for pancreatic ductal adenocarcinoma (PDAC) and neuroendocrine tumors</li>
            <li><strong>CD38-targeted PET agents</strong> for multiple myeloma pharmacodynamic monitoring</li>
            <li><strong>Nectin-4 PET radiotracers</strong> for optimizing Enfortumab Vedotin therapy in urothelial carcinoma</li>
            <li><strong>PD-L1 imaging agents</strong> for cancer immunotherapy monitoring</li>
          </ul>
        </div>

        <div class="research-area">
          <h4>üß™ Radiochemistry Innovation</h4>
          <ul>
            <li>Development of <strong><sup>18</sup>F-fluorosulfate chemistry</strong> for late-stage peptide labeling</li>
            <li>Novel <strong>radiometal chelation strategies</strong> for targeted alpha therapy</li>
            <li><strong>Bioorthogonal click chemistry</strong> for site-specific radiolabeling</li>
            <li>Creation of <strong><sup>18</sup>F-radiometal theranostic pairs</strong> (Patent pending)</li>
          </ul>
        </div>

        <div class="research-area">
          <h4>üè• Cancer Applications</h4>
          <ul>
            <li><strong>Ovarian Cancer:</strong> EphA2-binding radiotherapeutics (HERA Foundation funded)</li>
            <li><strong>Pancreatic Cancer:</strong> Alpha particle theranostics for PDAC treatment</li>
            <li><strong>Multiple Myeloma:</strong> CD38-specific PET imaging for treatment monitoring</li>
            <li><strong>Neuroendocrine Tumors:</strong> EphA2-targeted molecular radiotheranostics (ERF/NETRF funded)</li>
            <li><strong>Colorectal Cancer:</strong> Albumin-bound EphA2-targeted radiotherapeutics</li>
            <li><strong>Bladder Cancer:</strong> Nectin-4 targeted imaging for personalized therapy</li>
          </ul>
        </div>

        <div class="research-area">
          <h4>‚öóÔ∏è Chemical Biology & ROS Research</h4>
          <ul>
            <li><strong>Photocontrolled ROS generation</strong> for antimicrobial applications</li>
            <li><strong>Visible-light triggered H<sub>2</sub>S release</strong> for therapeutic applications</li>
            <li><strong>Redox-guided antimycobacterial agents</strong> for tuberculosis treatment</li>
            <li><strong>Peroxynitrite-based probes</strong> for studying bacterial redox homeostasis</li>
          </ul>
        </div>
      </div>

      <div class="techniques-section">
        <h3>Techniques & Methodologies</h3>
        
        <div class="technique-category">
          <h4>üî¨ Synthetic Chemistry</h4>
          <ul>
            <li>Multi-step organic synthesis of small molecules</li>
            <li>Solid-phase peptide synthesis (linear and cyclic peptides)</li>
            <li>Peptide-drug conjugate development</li>
            <li>Antibody-drug conjugate synthesis</li>
            <li>Prosthetic group design and linker optimization</li>
          </ul>
        </div>

        <div class="technique-category">
          <h4>üìä Analytical Characterization</h4>
          <ul>
            <li>High Performance Liquid Chromatography (HPLC)</li>
            <li>Nuclear Magnetic Resonance (NMR) spectroscopy</li>
            <li>Mass Spectrometry (LC-MS, MALDI-TOF, HRMS)</li>
            <li>Column chromatography purification</li>
            <li>IR and CHNS elemental analysis</li>
          </ul>
        </div>

        <div class="technique-category">
          <h4>‚ò¢Ô∏è Radiochemistry</h4>
          <ul>
            <li>Radiosynthesis with <sup>18</sup>F, <sup>64</sup>Cu, <sup>68</sup>Ga, <sup>177</sup>Lu, <sup>225</sup>Ac</li>
            <li>Fluorosulfate-based <sup>18</sup>F labeling methodologies</li>
            <li>Radiometal chelation and complexation</li>
            <li>Quality control and radiochemical purity assessment</li>
            <li>Specific activity optimization</li>
          </ul>
        </div>

        <div class="technique-category">
          <h4>üß¨ Biological Evaluation</h4>
          <ul>
            <li>Cell culture with primary and cancer cell lines</li>
            <li>In vitro binding affinity and specificity assays</li>
            <li>Cellular uptake and internalization studies</li>
            <li>Cytotoxicity and therapeutic efficacy assessment</li>
            <li>Reactive species detection and quantification</li>
          </ul>
        </div>

        <div class="technique-category">
          <h4>üñºÔ∏è Imaging & In Vivo Studies</h4>
          <ul>
            <li>PET/CT and PET/MR imaging</li>
            <li>Small animal tumor xenograft models</li>
            <li>Biodistribution and pharmacokinetic studies</li>
            <li>Image analysis using Amira, Amide, and PMOD software</li>
            <li>Ex vivo autoradiography and histological analysis</li>
          </ul>
        </div>

        <div class="technique-category">
          <h4>üîç Specialized Techniques</h4>
          <ul>
            <li>Nitric oxide detection using Sievers 280i analyzer</li>
            <li>UV-visible spectroscopy and fluorometry</li>
            <li>Light irradiation techniques for photoactivation</li>
            <li>Fluorescence microscopy (EVOS‚Ñ¢ FL auto imaging system)</li>
            <li>Varioskan optical measurements</li>
          </ul>
        </div>
      </div>

      <div class="current-projects">
        <h3>Current Funded Projects</h3>
        
        <div class="project-item">
          <h4>EphA2-Targeted Radiotheranostics for Neuroendocrine Tumors</h4>
          <p class="funding-info"><strong>Funding:</strong> ERF/NETRF Nuclear Medicine Pilot Research Grant ($100,000, 2024-2026)</p>
          <p>Developing novel EphA2-targeted molecular radiotheranostics for lung neuroendocrine tumors, combining diagnostic imaging with targeted radiotherapy.</p>
        </div>

        <div class="project-item">
          <h4>EphA2-Binding Radiotherapeutic for Ovarian Cancer</h4>
          <p class="funding-info"><strong>Funding:</strong> HERA Ovarian Cancer Foundation Outside-the-Box Grant ($30,000, 2024)</p>
          <p>Creating innovative radiotherapeutic agents specifically targeting EphA2 receptors overexpressed in ovarian cancer for precision treatment.</p>
        </div>

        <div class="project-item">
          <h4>Albumin-Bound EphA2-Targeted Radiotherapeutics for Colorectal Cancer</h4>
          <p class="funding-info"><strong>Funding:</strong> Johns Hopkins Colorectal Cancer Research Center Pilot Award ($50,000, 2024-2025)</p>
          <p>Developing albumin-bound delivery systems for EphA2-targeted molecular radiotherapeutics to enhance treatment efficacy in colorectal cancer.</p>
        </div>
      </div>

      <div class="research-statement">
        <h3>Research Philosophy</h3>
        <p>Our research is driven by the vision of advancing precision medicine through innovative radiopharmaceutical development. We bridge the gap between chemical innovation and biological impact, focusing on translational applications that can directly benefit cancer patients. Our multidisciplinary approach combines cutting-edge chemistry, advanced imaging technologies, and rigorous biological validation to develop next-generation theranostic agents.</p>
        
        <p>We are committed to mentoring the next generation of scientists and fostering collaborative relationships across disciplines. Our motto, <em>"Chase curiosity, create impact,"</em> reflects our dedication to pursuing fundamental scientific questions while maintaining a clear focus on clinical translation and patient benefit.</p>
      </div>
    </section>
  </main>

  <footer>
    <p>&copy; 2025 Ajay Kumar Sharma Lab, Johns Hopkins University</p>
  </footer>

  <style>
    .research-areas {
      margin: 2rem 0;
    }

    .research-area {
      background: #f8fafc;
      padding: 1.5rem;
      margin-bottom: 1.5rem;
      border-radius: 8px;
      border-left: 4px solid #3b82f6;
    }

    .research-area h4 {
      margin-top: 0;
      color: #1e40af;
      font-size: 1.25rem;
    }

    .techniques-section {
      margin: 2rem 0;
      background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%);
      padding: 2rem;
      border-radius: 12px;
      border: 2px solid #3b82f6;
    }

    .techniques-section h3 {
      margin-top: 0;
      color: #1e3a8a;
    }

    .technique-category {
      background: white;
      padding: 1.5rem;
      margin-bottom: 1.5rem;
      border-radius: 8px;
      border-left: 4px solid #10b981;
    }

    .technique-category h4 {
      margin-top: 0;
      color: #059669;
      font-size: 1.1rem;
    }

    .current-projects {
      margin: 2rem 0;
    }

    .project-item {
      background: #f1f5f9;
      padding: 1.5rem;
      margin-bottom: 1.5rem;
      border-radius: 8px;
      border-left: 4px solid #f59e0b;
    }

    .project-item h4 {
      margin-top: 0;
      color: #d97706;
      font-size: 1.25rem;
    }

    .funding-info {
      font-weight: 600;
      color: #059669;
      margin-bottom: 1rem;
    }

    .research-statement {
      background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
      padding: 2rem;
      border-radius: 12px;
      border: 2px solid #f59e0b;
      margin-top: 2rem;
    }

    .research-statement h3 {
      margin-top: 0;
      color: #d97706;
    }

    .research-statement p {
      line-height: 1.7;
    }
  </style>
</body>
</html>